VTRS Stock: Price, Earnings History and SEC Filings
Viatris Inc. (VTRS) last traded at $19.04, down 0.86% on the latest session and up 7.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.69 against an analyst estimate of $0.62, a beat of 11.3%.
$19.04 -0.86%
1 month+7.42%
52-week high$19.51
52-week low$9.92
Volume8.79M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VTRS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.69 | $0.62 | +11.29% |
| Mar 2026 | May 7, 2026 | $0.59 | $0.52 | +13.46% |
| Dec 2025 | Feb 26, 2026 | $0.57 | $0.52 | +9.62% |
| Sep 2025 | Nov 6, 2025 | $0.67 | $0.63 | +6.35% |
VTRS beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for VTRS
SEC filing data is not available right now. You can search for VTRS on SEC EDGAR.
VTRS news
- 4 Medical Stocks With a Healthy Shot at Q3 Earnings BeatsOct 30, 2026 · finance.yahoo.com
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.Oct 30, 2026 · finance.yahoo.com
- Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?Oct 30, 2026 · stocktwits.com
- RYZUMVI Approval Could Be A Key Test For Viatris Stock (VTRS)Oct 29, 2026 · finance.yahoo.com
- Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- 1 stock under $50 worth investigating and 2 we ignoreOct 29, 2026 · finance.yahoo.com
- 1 cash-producing stock with competitive advantages and 2 we brush offOct 29, 2026 · finance.yahoo.com
- Viatris (VTRS) Wins FDA Approval For RYZUMVI In Adult PresbyopiaOct 28, 2026 · finance.yahoo.com
About Viatris Inc.
Viatris Inc. (VTRS) is a US-listed public company on Nasdaq.